KDR and small cell lung carcinoma: This was the first phase 2 study evaluating the combination of an immune checkpoint inhibitor with anti-VEGFR in patients with advanced SCLC and the reported positive results support further clinical studies of camrelizumab plus apatinib in SCLC.